Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.
作者信息
Nathwani Nitya, Palmer Joycelynne, Synold Timothy W, Salehian Behrouz, Rosenzweig Michael, Sanchez James F, Hammond Samantha N, Adekola Kehinde, Tomarchio Valeria, Chowdhury Arnab, Karanes Chatchada, Htut Myo, Sahebi Firoozeh, Siddiqi Tanya, Krishnan Amrita, Forman Stephen J, Rosen Steven T
机构信息
Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA.
Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA; Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
出版信息
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e667-e672. doi: 10.1016/j.clml.2020.05.017. Epub 2020 May 29.
Abstract
摘要
相似文献
1
Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤中二甲双胍/利托那韦联合治疗相关的毒性反应
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e667-e672. doi: 10.1016/j.clml.2020.05.017. Epub 2020 May 29.
2
Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.使用美国食品药品监督管理局（FDA）批准的利托那韦和二甲双胍靶向多发性骨髓瘤的代谢可塑性。
Clin Cancer Res. 2015 Mar 1;21(5):1161-71. doi: 10.1158/1078-0432.CCR-14-1088. Epub 2014 Dec 26.
3
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).使用HIV蛋白酶抑制剂奈非那韦进行治疗可引发未折叠蛋白反应，并且与硼替佐米联合使用时可能克服多发性骨髓瘤对蛋白酶体抑制剂的耐药性：一项I期试验（SAKK 65/08）。
Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.
4
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
5
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.美法仑氟芬酰胺联合地塞米松治疗复发难治性多发性骨髓瘤（O-12-M1）：一项多中心、国际性、开放标签的1/2期研究
Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
6
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Leuk Lymphoma. 2007 Jan;48(1):39-45. doi: 10.1080/10428190600909578.
7
Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.洛匹那韦/利托那韦和奈非那韦引起的卡马西平毒性。
Ann Pharmacother. 2006 Jun;40(6):1190-5. doi: 10.1345/aph.1G630. Epub 2006 May 23.
8
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].基于硼替佐米的复发或难治性多发性骨髓瘤联合疗法
Zhonghua Nei Ke Za Zhi. 2008 Feb;47(2):102-6.
9
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.利托那韦、奈非那韦及洛匹那韦/利托那韦在接受过抗逆转录病毒治疗的HIV感染儿童中的长期安全性和有效性
Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.
10
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):236-45. doi: 10.1097/00126334-200003010-00004.
引用本文的文献
1
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.一项评估米哚妥林联合维奈托克治疗复发/难治性急性髓系白血病患者的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性、剂量递增和扩展研究
Clin Lymphoma Myeloma Leuk. 2024 May;24(5):298-304. doi: 10.1016/j.clml.2024.01.002. Epub 2024 Jan 6.
2
Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.多发性骨髓瘤肿瘤微环境中耐药性背后的代谢变化。
Front Oncol. 2023 Apr 6;13:1155621. doi: 10.3389/fonc.2023.1155621. eCollection 2023.
3
Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance.多发性骨髓瘤的代谢改变：从肿瘤发生到蛋白酶体抑制剂耐药性
Cancers (Basel). 2023 Mar 9;15(6):1682. doi: 10.3390/cancers15061682.
4
The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus.二甲双胍起始使用者中多发性骨髓瘤风险降低：一项针对台湾2型糖尿病患者的回顾性队列研究
Cancers (Basel). 2022 Nov 17;14(22):5637. doi: 10.3390/cancers14225637.
本文引用的文献
1
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.二甲双胍对 2 型糖尿病肾病患者的长期影响。
Diabetes Care. 2020 May;43(5):948-955. doi: 10.2337/dc19-0936. Epub 2020 Mar 4.
2
HIV protease inhibitors for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的HIV蛋白酶抑制剂。
Clin Adv Hematol Oncol. 2019 Nov;17(11):615-623.
3
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).来那度胺难治性多发性骨髓瘤患者中应用奈非那韦和来那度胺/地塞米松：一项 I/II 期试验（SAKK 39/10）。
Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2.
4
ReDO_DB: the repurposing drugs in oncology database.ReDO数据库：肿瘤学领域药物重新利用数据库。
Ecancermedicalscience. 2018 Dec 6;12:886. doi: 10.3332/ecancer.2018.886. eCollection 2018.
5
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.奈非那韦-硼替佐米-地塞米松在蛋白酶体抑制剂难治性多发性骨髓瘤中显示出有前景的活性。
Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.
6
Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.二甲双胍使用与肾功能范围内乳酸酸中毒风险的关联：一项基于社区的队列研究。
JAMA Intern Med. 2018 Jul 1;178(7):903-910. doi: 10.1001/jamainternmed.2018.0292.
7
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
8
Metformin-associated lactic acidosis: Current perspectives on causes and risk.二甲双胍相关乳酸酸中毒：病因与风险的当前观点
Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.
9
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).使用HIV蛋白酶抑制剂奈非那韦进行治疗可引发未折叠蛋白反应，并且与硼替佐米联合使用时可能克服多发性骨髓瘤对蛋白酶体抑制剂的耐药性：一项I期试验（SAKK 65/08）。
Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11.
10
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.人类免疫缺陷病毒蛋白酶抑制剂利托那韦对泌尿系统恶性肿瘤可能具有活性。
Onco Targets Ther. 2015 Apr 8;8:761-8. doi: 10.2147/OTT.S79776. eCollection 2015.
Zotero 插件